“To be eligible for any cooperation credit, corporations must provide to the Department all relevant facts about the individuals involved in corporate misconduct.”

**September 9, 2015 Deputy Attorney General Sally Yates Memorandum for All United States Attorneys

These are the words that rang through the halls of pharma corporate headquarters across the nation moments after they were announced. The industry is buzzing with what this enforcement priority will look like and what needs to change in their compliance programs to prepare for it.

Come hear from 12 federal enforcers on how they have and will be moving on this directive

This year we return this iconic and industry leading conference: Fraud and Abuse in the Sales & Marketing of Drugs to the jurisdiction with the strongest arm of enforcement in the nation, Massachusetts. As such, not only will we have an unparalleled faculty of government enforcers, including two from Boston, but we will also be featuring United States Attorney Carmen Ortiz, who will deliver a keynote address to open this event with insight into what the DOJ’s enforcement priorities are.

It started with AMARIN, and PACIRA followed…where do we go from here…
Attend the One Event that has that will provide you with both Government and Industry Leaders’ Insights on where Off-Label Promotion is NOW and what that means for your compliance program

You can’t afford to miss hearing from those on the front lines. After receiving first hand insights from the enforcers, benchmark with industry leaders such as AbbVie, Bayer HealthCare, LLC, Eli Lilly and Company, Endo Pharmaceuticals Inc., Gilead Sciences Inc., Indivior, Novo Nordisk, Pfizer, Prometheus Laboratories, Inc., Upsher-Smith, Vertex Pharmaceuticals and many more on the most critical issues facing the pharmaceutical industry today, including:

  • Individual Accountability for Corporate Wrongdoing: The Ripple Effect of the Yates Memo
  • Patient support programs, Investigator-Initiated Studies and Anti-Kickback pitfalls
  • Establishing ethical parameters between Commercial and R&D early to avoid regrets later
  • Adapting compliance protocols to ACA requirements and the changing pharmaceutical industry
  • Utilizing marketing opportunities in social media while avoiding the landmines
  • Economic and Regulatory Shifts in the Global Marketplace

ACI’s 16th Annual Forum on Fraud and Abuse in the Sales and Marketing of Drugs will once again provide a forum for compliance professionals and attorneys to engage with top government enforcers, benchmark with peer in-house doyens and senior compliance executives. Participate in high-level discussion and analysis of the most recent decisions, settlements and guidance so you can ensure your marketing compliance protocols remain up-to-date in this unparalleled time of government scrutiny and examination.

Register now to ensure your spot at this crucial event by calling 888-224-2480, by fax at 877-927-1563, or online.